The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study
Susan O’Brien(University of California, Irvine), John C. Byrd(University of Cincinnati), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Richard R. Furman(Cornell University), Steven Coutré(Georgetown University), Tasheda Navarro(Pharmacyclics (United States)), Amy J. Johnson(Ouranos), Eric Hedrick(Florida Hospital Cancer Institute), Kristie A. Blum(Emory University), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Nyla A. Heerema(The Ohio State University), Barbara Grant(University of Vermont), Eric Holmgren(Pharmacyclics (United States)), Ian W. Flinn(Tennessee Oncology)
Cited by 56
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k